[ad_1]
(Alliance Information) – HealthBeacon PLC on Wednesday stated it was deploying its “international affected person security know-how platform” throughout the NHS and pharmaceutical trade in Eire, Australia and New Zealand.
HealthBeacon is a Dublin-based digital therapeutics firm creating challenge for managing injectable medicines.
The platform, developed during the last two years in collaboration with the pharmaceutical trade, helps most cancers sufferers take medicine “extra safely”.
Platform is designed to “change a paper-based system” to make sure the appropriate folks get entry to the appropriate medication. HealthBeacon stated it is going to additionally “drive down the price of administration”.
Based on HealthBeacon, the platform creates a “new recurring income stream”. It anticipates the know-how will help greater than 1,000 sufferers by the top of 2022.
Thus far greater than 800 pharmacies have already adopted the system throughout Eire and the UK and 12 pharmaceutical firms have purchased licenses to switch their paper-based system with HealthBeacon’s streamlined software program.
The primary drug to be prescribed on the platform is Lenalidomide, used to deal with sure cancers.
If Lenalidomide is taken throughout being pregnant, it poses a danger of start defects, HealthBeacon stated. Utilizing a collection of digital checks and balances, HealthBeacon’s platform ensures the medicine can’t be distributed till a set of agreed security protocols have been validated.
Co-founder & Chief Know-how Officer Kieran Daly: “The Affected person Security Platform is a pure development for HealthBeacon. Our digital therapeutics techniques are designed to spice up well being outcomes for sufferers. Our Good Sharps Bin has been designed to make sure sufferers take their injectable medicine in the simplest method. Now we’re utilizing our experience to design a brand new software program platform making certain one of the best outcomes for most cancers sufferers from their medicine.”
Shares in HealthBeacon closed up 0.9% at 2.30 pence on Wednesday in London.
By Chris Dorrell; chrisdorrell@alliancenews.com
Copyright 2022 Alliance Information Restricted. All Rights Reserved.
[ad_2]
Source link
